FIELD: oncology.
SUBSTANCE: group of inventions relates to the treatment of HER2-positive cancers. Provided are processes for treating or slowing the progression of HER2 positive cancer in a subject in need thereof, including administration of treatment regimen comprising an anti-HER2 antibody, such as trastuzumab, and a T-cell dependent bispecific (TDB) anti-HER2 antibody to the subject. Moreover, HER2 TDB contains a shoulder against HER2 and a shoulder against CD3, while both the anti-HER2 antibody and HER2 TDB bind domain IV to HER2.
EFFECT: inventions allow to reduce the non-tumour/target toxicity of HER2 TDB in HER2-expressing normal tissues, while essentially not affecting the antitumor activity of HER2 TDB in patients with HER2-positive tumours.
92 cl, 5 dwg, 4 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LY6G6D ANTIBODIES AND METHODS OF USE | 2020 |
|
RU2818569C1 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF THEIR USE | 2019 |
|
RU2800779C2 |
| HUMANIZED ANTIBODIES AND ANTIBODIES WITH MATURE AFFINITY AGAINST FcRH5 AND METHODS FOR THEIR APPLICATION | 2016 |
|
RU2748943C2 |
| HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
| ANTIBODIES, CAPABLE OF SPECIFIC CONNECTING WITH HER2 | 2014 |
|
RU2628094C2 |
| ANTI-HER2 ANTIBODY DRUGS FOR SUBCUTANEOUS INJECTION | 2018 |
|
RU2750821C2 |
| CD3 BINDING ANTIBODIES | 2017 |
|
RU2807216C2 |
| ANTIBODIES BINDING CD3 | 2017 |
|
RU2790288C2 |
| ANTIBODIES TO ICOS | 2016 |
|
RU2742241C2 |
| BISPECIFIC ANTIGEN-BINDING POLYPEPTIDES | 2015 |
|
RU2723940C2 |
